BEAM
Beam Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.23
−5.58%Oct 29, 2026, 09:51 UTC
Beam Therapeutics Inc. shares rose 15.6% in the last session on above-average trading volume.
Source:Oct 13, 2026, 11:00 UTC
Beam Therapeutics Inc. reported initial Phase 1/2 data for BEAM-301 showing restoration of endogenous glucose production after a single treatment and dose-dependent improvements in key GSDIa endpoints.
Source:Sep 29, 2026, 17:54 UTC
Beam Therapeutics filed a lawsuit accusing former scientist Zi Jun "Emma" Wang of stealing intellectual property to co-found Shanghai-based YolTech Therapeutics, with YolTech and Serapha Bio named as defendants.
Sep 2, 2026, 06:02 UTC
Beam Therapeutics appointed Eric Foster as chief commercial officer.
Source:Aug 4, 2026, 13:26 UTC
Beam Therapeutics Inc. reported a second-quarter loss of $1.18 per share, missing the Zacks Consensus Estimate of a loss of $1.00 per share.
Jul 8, 2026, 12:00 UTC
Prime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.
Jun 18, 2026, 11:00 UTC
The U.S. FDA cleared Beam Therapeutics' IND application for BEAM-304 for the treatment of phenylketonuria.
Source: